OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC

OncoCyte (NASDAQ:OCX) had its price objective boosted by stock analysts at Needham & Company LLC from $3.60 to $4.25 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective points to a potential upside of 77.08% from the stock’s previous close.

Several other brokerages have also issued reports on OCX. StockNews.com began coverage on OncoCyte in a research note on Wednesday. They set a “sell” rating on the stock. Benchmark reaffirmed a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a research note on Monday, April 15th. Finally, Stephens reaffirmed an “equal weight” rating and set a $4.00 price target on shares of OncoCyte in a research note on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.06.

OncoCyte Price Performance

OncoCyte stock traded down $0.06 on Wednesday, reaching $2.40. The company’s stock had a trading volume of 36,421 shares, compared to its average volume of 48,088. The business’s fifty day moving average price is $2.93 and its 200 day moving average price is $3.05. OncoCyte has a twelve month low of $2.08 and a twelve month high of $6.20.

Insider Transactions at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the transaction, the insider now owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the transaction, the insider now owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Andrew Arno purchased 33,898 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The shares were bought at an average cost of $2.95 per share, with a total value of $99,999.10. Following the completion of the transaction, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The disclosure for this purchase can be found here. Insiders bought 2,457,288 shares of company stock valued at $7,176,400 over the last three months. Company insiders own 1.94% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.